AlphAIAlphAI — Financial news for AI agents
investing.com$RKLB

Rocket Lab Q3 2026 slides: record $268M revenue, $3.6B backlog

Rocket Lab (RKLB) reported Q3 2026 revenue of $268M, up 73% YoY, with a record $3.6B backlog. Shares initially rose 10.91% before falling 7.1% after-hours. Gross margins beat guidance, but costs rose, widening the adjusted EBITDA loss to $18M. Space Systems and Launch segments drove growth, with new contracts signed at higher prices.

Original reporting
investing.com
Published Nov 9, 2026, 11:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 11:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$RKLB
Bearish
high confidence
Mentioned
$RKLB
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RKLBBearishHigh
01

Why it matters

The earnings miss triggered a 7% after‑hours decline after an initial 10% surge, indicating market concern over rising costs.

02

Market read

First‑report earnings with large revenue and backlog figures; significant price reaction makes it a high‑value trading event.

03

What to watch

Positive cash flow from milestone payments and a strong cash balance provide runway for continued investment.

Relevance 9/10Novelty 9/10Timing: after‑hours today

Background

Rocket Lab presented its Q3 2026 investor update, reporting record revenue and backlog while missing earnings expectations.

Company-level read

Ticker impact

$RKLBBearishHigh confidence
Context

Q3 2026 earnings release shows record revenue and backlog but a larger-than-expected loss, driving a volatile price move.

Expected impact

likely downside as investors price in the wider loss versus expectations

Evidence & confidence

Revenue beat is offset by a loss of $0.12 per share versus the expected $0.07 loss, prompting a sell‑off after the initial surge.

Market effects

Sector

Highlights growing demand for small‑satellite launch services, may boost peers in the launch sector.

Regional

U.S. space‑tech and defense stocks could see mixed reactions as investors weigh growth versus cost pressures.

Global

Backlog growth signals continued global satellite demand, but higher costs may temper broader aerospace sentiment.

Counterpoint

What could challenge this read

Despite the loss, the record backlog and pricing power on Neutron contracts could support upside if cost discipline improves.

Key entities

  • Executive
    Peter Beck

    CEO of Rocket Lab, quoted on record revenue and backlog.

  • Executive
    Adam Spice

    CFO, explained margin performance and cost drivers.

Read at source← All news

StoryRocket Lab posts record Q3 2026 revenue and backlog amid Neutron delay and Iridium acquisition

Also covered by

6 outlets

Related articles

$RKLBHighAI 8/10

Why Rocket Lab Stock Is Falling After Hours as Take-Two Surges — and What Wall Street Sees Next

Rocket Lab (RKLB) fell 4% after reporting a larger-than-expected loss despite revenue growth, while Take-Two (TTWO) rose 4% on strong preorders for Grand Theft Auto VI and reaffirmed annual outlook. RKLB's Q3 revenue grew 72.7% to $267.8M, but its loss of $0.12 per share missed estimates. TTWO's Q2 bookings missed forecasts but its updated fiscal 2027 outlook was raised. Both stocks have Strong Buy ratings from analysts.

tipranks.com
$RKLBHigh

Rocket Lab Q4 Guidance: Sales $270M-$290M vs $265.4M Est

Rocket Lab reported Q3 revenue of $267.83M, beating estimates, but posted a loss of $0.12 per share. The company guided Q4 revenue to $270M-$290M. Shares fell 6.61% in after-hours trading. Rocket Lab's backlog grew to $3.57B, with $1B in new launch contracts. The Neutron rocket's first launch is delayed to 2027. The company plans to acquire Iridium for $8B, with closing expected by mid-2027. Analysts have a Buy rating with an average price target of $103.23.

scanx.trade